Navigation Links
OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
Date:7/24/2009

ooking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceeds in respect of the financing, the company's manufacturing readiness, prospects for securing a co-development and commercialization partner and planned phase 3 trials. Such forward-looking statements are subject to risks and uncertainties, including, among others: the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
2. OncoGenex Pharmaceuticals Added to Russell Indexes
3. OncoGenex Pharmaceuticals Files Shelf Registration Statement
4. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
5. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
6. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
7. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
8. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
9. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
10. OncoGenex Reports First Quarter Financial Results
11. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Boston’s Adult Stem ... flush with innovative adult stem cell biotechnologies. Currently ... and has three additional patent applications currently under examination ... patented inventions address two of the most vexing problems ... Adult stem cells are difficult to identify; and ...
(Date:7/30/2014)... July 30, 2014 Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... and highlights for the quarter ended June 30, 2014 ... markets close. Regulus will host a ... at 5:00 pm Eastern Daylight Time to discuss its ...
(Date:7/30/2014)... 30, 2014 W. R. Grace ... of the REVELERIS® Prep purification system , ... chromatographers, and other researchers to perform both flash ... unit. , With the REVELERIS® Prep purification system, ... chromatography modes with a simple touch of the ...
(Date:7/30/2014)... A study presented at the 2014 ... of CSL Behring,s C1 Inhibitor (C1-INH) concentrate in ... sensitized patients. C1-INH is a human protein and ... The study shows that post-transplant treatment with ... of complement components 3 and 4, suggesting that ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Grace Launches New REVELERIS® Prep Purification System 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... long-term promise, non-invasive techniques can also provide effective ... in the brain for paralyzed patients with significantly ... applications for healthy users. However, two issues hamper ... on non-invasive recording techniques, such as electroencephalography (EEG). ...
... IRVINE, Calif., Aug. 12 ChromaDex,Corporation, (OTC Bulletin ... contract research, today announced financial results for the,second ... in accordance with,U.S. Generally Accepted Accounting Principles (GAAP), ... of $0.03 per share for the,three months ended ...
... ST. LOUIS, Aug. 12 At the Board ... quarterly cash dividend of,$.13 per share. The dividend ... record on September 2, 2008., About Sigma-Aldrich: ... company. Our biochemical and organic chemical products and ...
Cached Biology Technology:ChromaDex Announces Second Quarter 2008 Financial Results 2ChromaDex Announces Second Quarter 2008 Financial Results 3
(Date:7/30/2014)... black truffle uses reversible epigenetic processes to regulate its ... ,methylome, - a picture of the genome regulation taking ... access journal Genome Biology and illustrates how ... and ,jumping genes,. The authors say this may shed ... controlled. , Black truffles (Tuber melanosporum), also known as ...
(Date:7/30/2014)... protected and tended her eggs until they hatched 4.5 ... 2014 in the open-access journal PLOS ONE ... and colleagues. , Octopuses typically have a single reproductive ... take care of their fertilized eggs until they hatch. ... to 3 months, but little is known about the ...
(Date:7/30/2014)... effects of climate change on the world,s animal ... factors, according to a new paper by a ... of Queensland, and other organizations. The authors claim ... the point when it comes to climate change. ... scientists focus on the "direct" threats of changing ...
Breaking Biology News(10 mins):How black truffles deal with the jumpers in their genome 2Deep-sea octopus has longest-known egg-brooding period 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2
... and spend enormous resources on the conservation of endangered ... One big problem is international legislation and the need ... networks. Zoo resources can be spent much more effectively, ... animal collections across the world,s zoos. Many zoos ...
... and, in most cases, they have evolved a "circadian clock". ... has been shown to have important metabolic consequences for the ... on health; for example lack of sleep is linked with ... the ability to control body weight. Scientists from the ...
... Cell Research (ISSCR) has announced the following 2014 award ... Annual Meeting in Vancouver, taking place June 18-21, 2014: ... Research UK Gurdon Institute, for the McEwen Award for ... Yale Stem Cell Center, for the ISSCR-BD Biosciences Outstanding ...
Cached Biology News:Scientists warn: Conservation work in zoos is too random 2Scientists warn: Conservation work in zoos is too random 3The internal clock and feeding rhythm set the pace of the liver 2The International Society for Stem Cell Research announces its 2014 award recipients 2The International Society for Stem Cell Research announces its 2014 award recipients 3